| Literature DB >> 34599600 |
Rita Gaspari1,2, Giorgia Spinazzola1,2, Luciana Teofili3,4, Alfonso W Avolio5,6, Barbara Fiori7, Gian M Maresca1, Teresa Spanu2,7, Nicola Nicolotti8, Gennaro De Pascale1,2, Massimo Antonelli1,2.
Abstract
BACKGROUND/Entities:
Keywords: ESKAPEEc; SARS-CoV-2; hand hygiene; health care-associated infections; multidrug resistance; personal protective equipment
Mesh:
Year: 2021 PMID: 34599600 PMCID: PMC8646464 DOI: 10.1111/eci.13687
Source DB: PubMed Journal: Eur J Clin Invest ISSN: 0014-2972 Impact factor: 4.686
Demographics and clinical characteristics of patients with documented infection by ESKAPEEc pathogens
| PARAMETER | COVID−19 | Pre‐COVID−19 | 57 |
|
|---|---|---|---|---|
| Age, median (IQR), y | 70 (55–73) | 68 (53–79) | 0.726 | |
| Male | 17 (73.9) | 25 (71.4) | 1.000 | |
| Body mass index, median (IQR), Kg/m2 | 25.4 (23.7–29.4) | 26.6 (21.9–29.4) | 0.930 | |
| Indication for surgical ICU admission | ||||
| Major abdominal surgery including liver/kidney transplant | 18 (78.2) | 27 (77.1) | 0.431 | |
| Vascular surgery | 3 (13.0) | 3 (8.6) | ||
| Trauma surgery | 2 (8.7) | 1 (2.3) | ||
| Cerebral Hemorrhage | 0.0 | 3 (8.6) | ||
| Orthopedic surgery | 0.0 | 1 (2.9) | ||
| Most relevant comorbidities | ||||
| Chronic lung disease | 8 (34.8) | 11 (31.4) | 1.000 | |
| Type 2 diabetes | 4 (17.4) | 7 (20.0) | 1.000 | |
| Hypertension | 15 (56.5) | 16 (45.7) | 0.591 | |
| Ischemic heart disease | 5 (26.7) | 8 (22.9) | 1.000 | |
| Cancer | 11 (47.8) | 14 (40.0) | 0.596 | |
| ASA class | ||||
| 2 | 4 (17.4) | 4 (11.4) | 0.281 | |
| 3 | 5 (21.7) | 17 (48.6) | ||
| 4 | 12 (52.2) | 9 (25.7) | ||
| 5 | 2 (8.7) | 5 (14.3) | ||
| Surgical complexity | ||||
| 3 | 5 (21.7) | 7 (20.0) | 0.353 | |
| 4 | 18 (78.3) | 25 (71.4) | ||
| Hospital LoS pre‐ICU, median (IQR), d | 2 (0–8) | 2 (1–11) | 0.711 | |
| SAPS II, median (IQR) | 39 (33–48) | 46 (36–58) | 0.143 | |
| Elective surgery | 6 (26.1) | 11 (31.4) | 0.772 | |
| Surgical time (min) | 191 (140–383) | 175 (70–430) | 0.599 | |
| Mechanical ventilation (hours) | 96 (24–214) | 73 (36–200) | 0.886 | |
| Tracheotomy | 6 (26.0) | 5 (14.3) | 0.315 | |
| ICU LoS, median (IQR), d | 11 (7–18) | 8 (4–16) | 0.225 | |
| ICU death | 4 (17.4) | 13 (37.1) | 0.144 | |
| 28 days hospital mortality | 6 (26.1) | 17 (48.6) | 0.106 | |
Abbreviations: ASA, American Society of Anesthesiologists; ICU, intensive‐care unit; IQR, Interquartile range; LoS, length of stay; SAPS II, Simplified Acute Physiology Score II.
Epidemiology and infection site of ESKAPEEc pathogens
| PATHOGEN, RESISTANCE, and INFECTION SITE | COVID−19 | Pre‐COVID−19 | Total |
|
|---|---|---|---|---|
| Microorganisms | ||||
|
| 5 (21.7) | 8 (22.9) | 13 | 1.000 |
| VRE | 0 | 5 (14.3) | 5 | 0.145 |
|
| 4 (17.4) | 9 (25.6) | 13 | 0.533 |
| MRSA | 3 (13.0) | 6 (17.1) | 9 | 1.000 |
|
| 6 (26.1) | 8 (22.9) | 14 | 1.000 |
| Carbapenemase‐producing | 3 (60.0) | 5 (62.5) | 8 | 1.000 |
|
| 0 | 8 (22.9) | 8 | 0.017 |
| XDR | 0 | 8 (22.9) | 8 | 0.017 |
|
| 2 (8.7) | 5 (14.3) | 7 | 0.691 |
| MDR | 2 (8.7) | 2 (5.7) | 4 | 1.000 |
|
| 8 (34.8) | 5 (14.3) | 13 | 0.106 |
| MDR | 1 (4.3) | 1 (2.9) | 2 | 1.000 |
|
| 6 (26.1) | 17 (48.6) | 23 | 0.106 |
| ESBL‐producing | 0 | 8 (22.9) | 8 | 0.017 |
| Infection Site | ||||
| Ventilator‐acquired pneumonia | 11 (47.8) | 16 (45.7) | 27 | 1.000 |
| Hospital‐acquired pneumonia | 2 (8.6) | 2 (5.7) | 4 | 1000 |
| Skin and aoft‐tissue infection | 1 (4.3) | 6 (17.0) | 7 | 0.225 |
| Intra‐abdominal infection | 8 (34.8) | 7 (20.0) | 15 | 0.234 |
| Urinary tract infection | 1 (4.3) | 4 (11.4) | 5 | 0.638 |
| Bloodstream infection | 4 (17.4) | 7 (20.0) | 11 | 1.000 |
| Rectal swab | 1(4.3) | 4 (11.4) | 5 | 0.638 |
Abbreviations: ESBL, Extended spectrum beta‐lactamase; MDR, Multidrug‐resistant; MRSA, Methicillin‐resistant Staphylococcus aureus; VRE, Vancomycin‐resistant enterococcus; XDR, Extensively drug‐resistant.